Want to see AU:PER full AI Analyst Report?
Top Page
Percheron Therapeutics
(Sydney:PER)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$0.01
▲(0.00% Upside)
Action:Reiterated
Date:08/21/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and persistent cash burn), implying continued reliance on external funding despite low debt. Limited technical data results in a neutral technical contribution, while valuation remains pressured by negative earnings and the absence of dividend yield data.
Positive Factors
Low Leverage
Minimal debt reduces interest and refinancing pressure, giving Percheron greater financial flexibility as it advances its clinical programs. This limits balance-sheet risk, although it does not remove the need for funding while the company remains pre-commercial.
Negative Factors
No Revenue Base
The absence of revenue confirms that Percheron has not yet established a commercial product base or recurring operating income. This leaves results dependent on development progress and external capital until a candidate can be approved and commercialized.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Minimal debt reduces interest and refinancing pressure, giving Percheron greater financial flexibility as it advances its clinical programs. This limits balance-sheet risk, although it does not remove the need for funding while the company remains pre-commercial.
Read all positive factors
Percheron Therapeutics (PER) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$7.61M
Dividend YieldN/A
Average Volume (3M)2.49M
Price to Earnings (P/E)―
Beta (1Y)0.13
Revenue GrowthN/A
EPS Growth72.60%
CountryAU
Employees8
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,522,415,500
10 Day Avg. Volume2,742,659
30 Day Avg. Volume2,485,493
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.47
Price to Sales (P/S)0.00
P/FCF Ratio-0.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Percheron Therapeutics Business Overview & Revenue Model
Company Description
Percheron Therapeutics Limited, an Australian enterprise established in 2000 with its headquarters in Melbourne, is dedicated to the research and development of groundbreaking antisense pharmaceuticals. Formerly known as Antisense Therapeutics Lim...
How the Company Makes Money
null...
Percheron Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -219.56K | -67.98K | -79.42K | -95.20K | -89.22K |
| EBITDA | -5.40M | -16.27M | -11.84M | -13.25M | -7.52M |
| Net Income | -4.79M | -14.92M | -11.92M | -11.38M | -5.81M |
Balance Sheet | |||||
| Total Assets | 8.22M | 12.44M | 14.53M | 12.84M | 22.44M |
| Cash, Cash Equivalents and Short-Term Investments | 4.05M | 10.17M | 11.87M | 10.97M | 19.23M |
| Total Debt | 27.79K | 25.86K | 39.87K | 142.10K | 227.40K |
| Total Liabilities | 692.18K | 2.43M | 5.17M | 2.87M | 1.30M |
| Stockholders Equity | 7.53M | 10.00M | 9.36M | 9.98M | 21.14M |
Cash Flow | |||||
| Free Cash Flow | -4.97M | -15.65M | -10.12M | -8.18M | -7.81M |
| Operating Cash Flow | -4.96M | -15.64M | -10.12M | -8.15M | -7.81M |
| Investing Cash Flow | -3.09M | -7.24K | -3.61K | -29.29K | -3.91K |
| Financing Cash Flow | 1.93M | 13.95M | 11.02M | -85.30K | 21.02M |
Percheron Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$57.96M | -14.78 | -1.67% | ― | 15.21% | -141.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$20.54M | 21.67 | 1.66% | 6.67% | 5.74% | -222.22% | |
50 Neutral | AU$17.27M | -7.34 | -13.81% | ― | 5.93% | 66.32% | |
48 Neutral | AU$4.98M | 0.35 | 93.89% | ― | -29.95% | ― | |
45 Neutral | AU$7.61M | -1.22 | -65.33% | ― | ― | 72.60% | |
39 Underperform | AU$20.02M | -5.07 | 4388.00% | ― | -53.90% | 57.52% |
* Healthcare Sector Average
AU:PER
Percheron Therapeutics
0.01
0.00
0.00%
AU:CAN
Cann Group
0.01
>-0.01
-16.67%
AU:LGP
Little Green Pharma Ltd.
0.07
-0.05
-43.33%
AU:PKP
Althea Group Holdings Ltd.
0.01
>-0.01
-39.13%
AU:IDT
IDT Australia Limited
0.05
-0.02
-32.84%
AU:VIT
Cronos Australia Ltd.
0.03
-0.04
-60.61%
Percheron Therapeutics Corporate Events
Percheron Therapeutics Corrects Auditor Report Omission in FY2026 Annual Filing
Aug 19, 2026
Percheron Therapeutics has disclosed that its electronic FY2026 annual report released to the ASX on 19 August 2026 inadvertently omitted the final page of the Independent Auditor’s Report due to an error in the external design and productio...
Percheron Therapeutics Files ASX Corporate Governance Statement and Appendix 4G
Aug 19, 2026
Percheron Therapeutics Limited, an ASX-listed biotechnology company, has published its corporate governance statement for the year ended 30 June 2026 on its website, detailing how it complies with ASX Corporate Governance Council principles. The s...
Percheron Therapeutics Adds New Shares to ASX Quotation
Aug 14, 2026
Percheron Therapeutics Limited has applied for quotation of 2,850 new ordinary fully paid shares on the Australian Securities Exchange, with an issue date of August 14, 2026. The small equity issuance arises from the exercise or conversion of exis...
Percheron Therapeutics names Michael Baker CEO as James Garner moves to non-executive role
Aug 9, 2026
Percheron Therapeutics has announced a leadership transition, with current Chief Executive Officer and Managing Director James Garner set to step down on 31 August 2026 to pursue an overseas opportunity, while remaining on the board as a non-execu...
Percheron Advances Lead Cancer Drug Minperstobart and Raises $2.2m for New Trial
Jul 30, 2026
Percheron Therapeutics reported continued progress in the June quarter as it advances its lead oncology candidate HMBD-002 toward mid-stage trials. The World Health Organization has granted the drug the provisional international non-proprietary na...
Percheron Completes Manufacture of HMBD-002 Drug Substance for 2026 Trial
Jun 16, 2026
Percheron Therapeutics has completed manufacturing of a new batch of HMBD-002 drug substance, produced under a license agreement by Hummingbird Bioscience, with testing confirming that quality attributes meet expected standards. Final release and ...
Percheron Therapeutics Issues New Tranche of Unquoted Equity Securities
Jun 1, 2026
Percheron Therapeutics has issued 13.75 million unquoted options under the ASX code PERAQ, exercisable at A$0.01 and expiring on April 15, 2028, alongside a further 13.75 million unquoted securities in a new class to be confirmed. The move, execut...
Percheron Therapeutics Plans Issue of 13.75 Million Options to Bolster Capital
May 29, 2026
Percheron Therapeutics has notified the ASX of its intention to issue up to 13,750,000 options, each exercisable at $0.01 and expiring on April 15, 2028. The options are proposed to be issued on June 1, 2026, as part of a placement or other type o...
WHO assigns proposed nonproprietary name to Percheron’s cancer drug HMBD-002
May 26, 2026
Percheron Therapeutics announced that the World Health Organization has selected “minperstobart” as the proposed international nonproprietary name for its investigational VISTA-targeting cancer therapy HMBD-002. The company expects the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.